Investment Analysts’ Updated EPS Estimates for August, 15th (BRO, CDXC, CLBS, CLD, CLSN, CSRMY, CW, CWH, CXW, DTEGY)
Brown & Brown (NYSE:BRO) had its hold rating reaffirmed by analysts at Wells Fargo & Company.
Chromadex Corp (OTCMKTS:CDXC) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex’s core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company’s main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. “
Caladrius Biosciences (NASDAQ:CLBS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $4.75 target price on the stock. According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “
Cloud Peak Energy (NYSE:CLD) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Cloud Peak Energy operates as a producer of low sulfur, high quality, sub-bituminous coal in the United States. It owns and operates three surface coal mines in the Powder River Basin named: Antelope, Cordero Rojo and the Spring Creek Mine. The Antelope Mine and Cordero Rojo Mine are located in Wyoming and the Spring Creek Mine is located near Decker, Montana. The company is headquartered in Gillette, Wyoming. “
Celsion Corporation (NASDAQ:CLSN) had its hold rating reaffirmed by analysts at Maxim Group.
Consort Medical plc (NASDAQ:CSRMY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Consort Medical Plc engages in the design, development, manufacture and sale of medical drug delivery devices. It operates through the Bespak and Aesica segments. Bespak segment develops and produces drug delivery devices which serves pharmaceutical companies with inhaler and auto-injector technologies. Aesica segment is a contract development and manufacturing organization which serves pharmaceutical firms with active pharmaceutical ingredient and finished dose formulation development and manufacturing services. Consort Medical Plc is headquartered in Hemel Hempstead, United Kingdom. “
Curtiss-Wright Corporation (NYSE:CW) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “CURTISS-WRIGHT CORP. produces precision components for the aerospace, industrial and marine companies. Aerospace components consist of control and actuation systems. Co. also provides shot-perring & heat treating for industrial markets and the target rock subsidiary produces engineered valves for the United States Navy. “
Camping World Holdings (NYSE:CWH) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $39.00 target price on the stock. According to Zacks, “Camping World Holdings, Inc. is a provider of services, protection plans, products and resources for recreational vehicle enthusiasts. The company’s brand consists of Camping World and Good Sam. It offers new and used RVs for sale, vehicle service and maintenance through retail locations and membership clubs. Camping World Holdings, Inc. is based in Lincolnshire, United States. “
Corrections Corp. of America (NYSE:CXW) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $29.00 target price on the stock. According to Zacks, “CoreCivic, Inc. is a real estate investment trust which provides correctional, detention and residential reentry facilities. It designs, constructs, owns, manages and renovates jails, prisons, government agencies and inmate transportation companies. CoreCivic, Inc., formerly known as Corrections Corporation of America, is based in Nashville, Tennessee. “
Deutsche Telekom AG (NASDAQ:DTEGY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Deutsche Telekom is Europe’s largest communications company and one of the largest communications carriers worldwide. Through T-Mobile, Deutsche Telekom’s mobile telephony subsidiary, and through other subsidiaries and investments, Deutsche Telekom serves mobile telephony customers worldwide. Deutsche Telekom offers its customers a complete range of fixed-line voice telephony products and services. “
Enzo Biochem (NYSE:ENZ) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company’s three wholly-owned subsidiaries–Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company’s research is the development of products based on two technology platforms — genetic modulation and immune modulation. “
Express (NYSE:EXPR) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Express, Inc. is a specialty retailer of women’s and men’s apparel in the United States. The Company operates retail outlets in high-traffic shopping malls, lifestyle centers and street locations across the United States. It also sells its products through its e-commerce website, express.com. Express targets women and men between 20 and 30 years of age. The Company offers its customers an edited assortment of apparel and accessories to address fashion needs across multiple aspects of their lifestyles, including work, casual and going-out occasions. Express, Inc. is headquartered in Columbus, Ohio. “
Genpact Limited (NYSE:G) was given a $33.00 target price by analysts at Cowen and Company. The firm currently has a buy rating on the stock.
Steven Madden (NASDAQ:SHOO) was given a $47.00 price target by analysts at Canaccord Genuity. The firm currently has a buy rating on the stock.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.